Try our mobile app

TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple Sclerosis

Published: 2020-12-10 12:12:00 ET
<<<  go to TGTX company page

Both studies met their primary endpoint of significantly reducingannualized relapse rate (ARR)(p